NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
DISOPHROL (dexbrompheniramine maleate; pseudoephedrine sulfate) by Merck & Co.. Approved for nasal congestion due to the common cold, hay fever, other upper repiratory allergies helps decongest sinus opening and 5 more indications.
Drug data last refreshed 15h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DISOPHROL is an oral tablet combining dexbrompheniramine maleate (first-generation antihistamine) and pseudoephedrine sulfate (nasal decongestant) for symptomatic relief of allergic rhinitis and upper respiratory congestion. It targets nasal congestion, sinus swelling, runny nose, sneezing, and itching associated with hay fever and the common cold. The antihistamine blocks H1 receptors to reduce allergic inflammation while the decongestant causes vasoconstriction to relieve nasal passage swelling.
Pre-Launch
Pre-launch status indicates imminent go-to-market activities; commercial teams should expect rapid scaling of field sales, marketing, and medical affairs positions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (8)
Worked on DISOPHROL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.